Heron Therapeutics Inc vs MakeMyTrip Ltd — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while MakeMyTrip Ltd trades at $53.21 (market cap $5.05B). The key difference: MakeMyTrip Ltd is far larger — about 55.2× Heron Therapeutics Inc's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | MMYT | |
|---|---|---|
Market Cap | $91.46M | $5.05B |
Sector | Health | Technology |
52-Week High | $1.96 | $103.21 |
52-Week Low | $0.39 | $36.30 |
Enterprise Value | $189.36M | $5.69B |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
MakeMyTrip (MMYT) trades at $53.22, down 2.56% on the day, with a bullish technical signal and strong analyst support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.25 exceeding expectations. Revenue for 2025 reached $978.34 million, though 2026 projections show a potential decline in net profit margin to 4.96%. Cash flow from operations remains healthy at $185.29 million, but a significant increase in liabilities is forecasted for 2026.
The outlook for MMYT is positive based on consistent earnings outperformance and a dominant market position in Indian online travel. Key risks include rising debt levels and travel demand volatility. With 72.73% of analysts rating it a Buy, the stock presents a growth opportunity, but investors must monitor execution against heightened financial leverage in the coming year.
Trailing returns across standard periods
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →